Guardant Health, Inc.
Guardant Health, Inc. (NASDAQ: GH) is a leading precision oncology company focused on transforming patient care through advanced blood and tissue-based testing, real-world data analytics, and artificial intelligence. The company's website is www.guardanthealth.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Guardant Health, Inc. does
In the company’s own words
Guardant Health, Inc. (NASDAQ: GH) is a leading precision oncology company focused on transforming patient care through advanced blood and tissue-based testing, real-world data analytics, and artificial intelligence. The company's website is www.guardanthealth.com.
Guardant Health operates across three primary business segments: therapy selection, minimal residual disease detection and recurrence monitoring, and early cancer screening. The therapy selection segment includes the Guardant360 CDx test, the first FDA-approved comprehensive liquid biopsy for tumor mutation profiling and companion diagnostic applications across non-small cell lung cancer, colorectal cancer, and breast cancer. The company also offers the Guardant360 Liquid test measuring over 740 genes and the Guardant360 Tissue test incorporating comprehensive multiomics analysis. The minimal residual disease segment features the Guardant Reveal test for detecting residual and recurring disease in early-stage cancer patients and monitoring therapy response in advanced-stage patients. The screening segment centers on the Shield blood test, the first FDA-approved blood test for primary colorectal cancer screening that meets Medicare coverage requirements.
Beyond clinical diagnostics, Guardant Health serves biopharmaceutical companies through its GuardantINFINITY and GuardantOMNI tests for clinical research and therapy development, along with the GuardantINFORM platform providing genomic and epigenetic insights into disease progression and treatment impact. The company's proprietary Smart Platform leverages genomic, epigenomic, and RNA-based data to deliver multiomic insights scalable from research to clinical applications.
Guardant Health operates clinical laboratories in Redwood City and Palo Alto, California, and Long Island City, New York, with research and development centers across multiple California locations. The company maintains a targeted sales organization focused on oncologists, cancer centers, and primary care physicians in the United States, while expanding internationally through partnerships with cancer centers, research organizations, and laboratory companies in Europe, Asia, the Middle East, and Africa. The company has established partnerships with leading institutions including Vall D'Hebron Institute of Oncology in Spain, The Royal Marsden NHS Foundation Trust in the United Kingdom, Policlinico Gemelli in Italy, and Adicon Holdings in China to advance global commercialization of its testing platform.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1576280
- SIC
- 8071
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Guardant Health, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Guardant Health, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Guardant Health, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Guardant Health, Inc.’s bonds, as funds hold them
Funds report holding 3 issues of Guardant Health, Inc.’s debt, $263.19M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.25%, maturing 2027 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Guardant Health, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Guardant Health, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Guardant Health, Inc.'s last four quarterly filings that the numbers alone won't show?”